Drug Trial Radar · NCT07665437
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
710
Planned (sponsor's estimate)
Start
Jul 10, 2026
Primary completion
Oct 15, 2031
Study completion Oct 15, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.
Conditions
- Hidradenitis Suppurativa
Interventions
RemibrutinibDrug
Remibrutinib Dose A and B (oral)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline, up to Week 280
Locations
61 sites in 12 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center PC
Birmingham, Alabama · Recruiting
Johnson Dermatology
Fort Smith, Arkansas · Recruiting
Arkansas Research Trials
North Little Rock, Arkansas · Recruiting
Ctr for Dermatology Clinical Res
Fremont, California · Recruiting
USC Keck School of Medicine
Los Angeles, California · Recruiting
Olive View UCLA Medical Center
Sylmar, California · Recruiting
Clinical Trials Research Institute
Thousand Oaks, California · Recruiting
University of MiamiHealth System
Miami, Florida · Recruiting
Floridian Research Institute
Miami, Florida · Recruiting
University Of South Florida
Tampa, Florida · Recruiting
Endeavor Health
Glenview, Illinois · Recruiting
Dundee Dermatology
West Dundee, Illinois · Recruiting
Southern IN Clinical Trials
New Albany, Indiana · Recruiting
Revival Research Institute
Troy, Michigan · Recruiting
Skin Specialists PC
Omaha, Nebraska · Recruiting
Cameron Dermatology
New York, New York · Recruiting
Icahn School Of Med At Mount Sinai
New York, New York · Recruiting
Skinsearch of Rochester Inc
Rochester, New York · Recruiting
OnSite Clinical Solutions LLC
Huntersville, North Carolina · Recruiting
Optima Research Boardman
Boardman, Ohio · Recruiting
Apex Clinical Research Center LLC
Mayfield Heights, Ohio · Recruiting
UP Medical Center H System
Pittsburgh, Pennsylvania · Recruiting
Clinical Research Ctr of Carolinas
Charleston, South Carolina · Recruiting
Medical University of South Carolina MUSC
Charleston, South Carolina · Recruiting
RFSA Dermatology
San Antonio, Texas · Recruiting
Center for Clinical Studies-Lee
Webster, Texas · Recruiting
Forefront Dermatology
Vienna, Virginia · Recruiting
Novartis Investigative Site
CABA, Argentina · Recruiting
Novartis Investigative Site
CABA, Argentina · Recruiting
Novartis Investigative Site
Caba, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina · Recruiting
Novartis Investigative Site
Sydney, New South Wales, Australia · Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia · Recruiting
Novartis Investigative Site
Parkville, Victoria, Australia · Recruiting
Novartis Investigative Site
Edmonton, Alberta, Canada · Recruiting
Novartis Investigative Site
London, Ontario, Canada · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Québec, Quebec, Canada · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.